Mycio Wealth Partners LLC Has $333,000 Holdings in Eli Lilly and Company (LLY)
Mycio Wealth Partners LLC continued to hold its position in shares of Eli Lilly and Company (NYSE:LLY) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,957 shares of the company’s stock at the end of the 2nd quarter. Mycio Wealth Partners LLC’s holdings in Eli Lilly and were worth $333,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently bought and sold shares of LLY. BlackRock Inc. increased its position in shares of Eli Lilly and by 2,628.5% during the first quarter. BlackRock Inc. now owns 62,260,488 shares of the company’s stock worth $5,236,731,000 after buying an additional 59,978,664 shares during the period. Vanguard Group Inc. increased its position in shares of Eli Lilly and by 3.3% during the first quarter. Vanguard Group Inc. now owns 68,597,006 shares of the company’s stock worth $5,769,694,000 after buying an additional 2,181,701 shares during the period. Winslow Capital Management LLC increased its position in shares of Eli Lilly and by 79.7% during the first quarter. Winslow Capital Management LLC now owns 3,875,968 shares of the company’s stock worth $326,008,000 after buying an additional 1,719,538 shares during the period. Harbour Capital Advisors LLC increased its position in shares of Eli Lilly and by 7,919.1% during the second quarter. Harbour Capital Advisors LLC now owns 1,705,338 shares of the company’s stock worth $20,721,000 after buying an additional 1,684,072 shares during the period. Finally, Renaissance Technologies LLC increased its position in shares of Eli Lilly and by 93.6% during the first quarter. Renaissance Technologies LLC now owns 2,980,400 shares of the company’s stock worth $250,681,000 after buying an additional 1,441,200 shares during the period. Institutional investors own 75.53% of the company’s stock.
In related news, major shareholder Lilly Endowment Inc sold 220,000 shares of the company’s stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $83.09, for a total value of $18,279,800.00. Following the transaction, the insider now owns 124,049,283 shares in the company, valued at approximately $10,307,254,924.47. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last quarter, insiders sold 990,000 shares of company stock worth $82,949,650. 0.20% of the stock is currently owned by company insiders.
TRADEMARK VIOLATION NOTICE: “Mycio Wealth Partners LLC Has $333,000 Holdings in Eli Lilly and Company (LLY)” was published by Daily Political and is owned by of Daily Political. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright law. The correct version of this report can be accessed at https://www.dailypolitical.com/2017/10/23/mycio-wealth-partners-llc-has-333000-holdings-in-eli-lilly-and-company-lly.html.
Eli Lilly and Company (LLY) opened at 87.23 on Monday. Eli Lilly and Company has a 1-year low of $64.18 and a 1-year high of $89.09. The company has a market capitalization of $92.03 billion, a price-to-earnings ratio of 37.75 and a beta of 0.34. The firm has a 50 day moving average of $84.38 and a 200-day moving average of $82.29.
Eli Lilly and (NYSE:LLY) last announced its quarterly earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.05 by $0.06. The company had revenue of $5.82 billion for the quarter, compared to analysts’ expectations of $5.60 billion. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. Eli Lilly and’s revenue was up 7.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.86 EPS. On average, equities research analysts anticipate that Eli Lilly and Company will post $4.16 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, December 8th. Investors of record on Wednesday, November 15th will be paid a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a yield of 2.38%. The ex-dividend date of this dividend is Tuesday, November 14th. Eli Lilly and’s payout ratio is 90.04%.
Several equities research analysts have recently weighed in on the stock. Morgan Stanley set a $86.00 price objective on shares of Eli Lilly and and gave the stock a “hold” rating in a research report on Friday, October 6th. BMO Capital Markets increased their price objective on shares of Eli Lilly and from $71.00 to $73.00 and gave the stock an “underperform” rating in a research report on Tuesday, October 10th. Credit Suisse Group cut shares of Eli Lilly and from an “outperform” rating to a “neutral” rating and increased their price objective for the stock from $84.23 to $88.00 in a research report on Tuesday, October 10th. Goldman Sachs Group, Inc. (The) reiterated a “buy” rating and set a $95.00 price objective (up from $92.00) on shares of Eli Lilly and in a research report on Thursday, October 5th. Finally, Piper Jaffray Companies reiterated a “buy” rating and set a $105.00 price objective on shares of Eli Lilly and in a research report on Friday, October 13th. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $88.97.
Eli Lilly and Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.